Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
In Pharma Media, Intent Is Becoming The Thing You Actually Buy
Kamya Elawadhi is Co-Founder and President at Doceree. For most of the history of pharma marketing, the unit of value has been reach. Brands have paid to be seen by as many of the right physicians as possible, and success has been measured in…
Guardian Pharma (GRDN) Q3 2026 Earnings Call Transcript
Vice President, Investor Relations - Ashley Stockton President and Chief Executive Officer - Fred Burke Chief Operating Officer - David Morris Chief Financial Officer - Will Mudd Residents Served -- 218,000, representing 7% growth compared to the…
Mayne Pharma sells Adelaide plant to focus on US
Mayne Pharma has agreed to sell its Adelaide manufacturing plant as part of a $55 million deal to offload its international segment to Genesis Capital following pressure from shareholders to break up the company after a $672 million takeover bid…
Atyr Pharma: Q3 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (ATYR) on Thursday reported a loss of $18.3 million in its third quarter. The San Diego-based company said it had a loss of $7.43 per share. Atyr Pharma shares have declined 81% since…
ARS Pharma (SPRY) Q3 2026 Earnings Call Transcript
President and Chief Executive Officer - Donn Casale Chief Commercial Officer - Meg Smith Chief Financial Officer - Kathleen Scott IR Representative - Monique Allaire Total Revenue -- $37.7 million, increasing from $32.5 million in the third quarter…
Eton Pharma (ETON) Q3 2026 Earnings Call Transcript
Chief Business Officer - David Krempa Chief Executive Officer - Sean Brynjelsen Chief Commercial Officer - Ipek Trinkaus Chief Financial Officer - Judith Matthews Net Revenue -- $57.9 million, representing 158% year-over-year growth driven by the…
ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript
President and Chief Executive Officer - Nikhil Lalwani Senior Vice President and Chief Financial Officer - Stephen Carey Senior Vice President and Head of ANI's Rare Disease Business - Christopher K. Mutz Chief Medical Officer - Gary Powell…
Ginkgo reaffirms 2026 cash burn guidance of $125M-$150M while outlining first pharma autonomous lab sale to Novo Nordisk (NYSE:DNA)
Earnings Call Insights: Ginkgo Bioworks (DNA) Q3 2026 “Over the last few years, we've been going through a transformation with this focus on autonomous labs, and that was really our goal in 2026. I would say I think that succeeded very…
Nuvectis Pharma (NASDAQ:NVCT) Shares Up 12.5% - Still a Buy?
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report)'s stock price rose 12.5% during mid-day trading on Friday. The company traded as high as $19.89 and last traded at $19.9810. Approximately 48,170 shares changed hands during mid-day trading, a…
HC Wainwright Lowers Earnings Estimates for Nuvectis Pharma
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Analysts at HC Wainwright decreased their FY2026 earnings per share estimates for Nuvectis Pharma in a research report issued on Wednesday, November 4th. HC Wainwright analyst J. Pantginis now…
Royalty Pharma (NASDAQ:RPRX) Given New $78.00 Price Target at Citigroup
Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its target price lifted by Citigroup from $70.00 to $78.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a 'buy' rating on the biopharmaceutical…
Urogen Pharma (NASDAQ:URGN) Stock Rated 'Moderate Buy' by Wall Street Analysts
Urogen Pharma (NASDAQ:URGN - Get Free Report) has earned a consensus recommendation of 'Moderate Buy' from the ten ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell…
NewAmsterdam Pharma (NASDAQ:NAMS) Given New $46.00 Price Target at Needham & Company LLC
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) had its price target lowered by stock analysts at Needham & Company LLC from $48.00 to $46.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a 'buy' rating on the…
Iovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market Reaction (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc., delivered strong Q3 results, with revenues up ~80% YoY and gross margin rising to 60%. IOVA reaffirmed 2026 guidance of $410–$420M revenue, and maintains a robust cash position ($376M) expected to last into…
Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income (NYSE:NVO)
Novo Nordisk A/S is upgraded to Strong Buy, driven by robust Q3 results and accelerating Wegovy pill adoption. Novo Nordisk trades at just 7.8x trailing operating income, well below pharma peers, supporting a value-driven investment thesis.
Receive a Daily briefing on Pharma Industry News
Get Started